Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …

Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …

Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …

Purpose Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib
pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC).
In preclinical models, combining EGFR and Src inhibition has additive synergistic effects …